使用可充电骶神经调控系统治疗尿急迫性尿失禁:ARTISAN-SNM 研究 6 个月结果
ARTISAN-SNM 关键研究纳入 129 例保守治疗失败的尿急迫性尿失禁患者,均植入可充电骶神经调控系统。6 个月时 90% 患者为治疗应答者,每日尿急迫性尿失禁发作次数从基线 5.6±0.3 次降至 1.3±0.2 次,ICIQ-OABqol 改善 34 分,无器械相关严重不良事件。
要点
- 6 个月时 90% 植入患者达到治疗应答(尿急迫性尿失禁发作较基线减少≥50%)。
- 每日发作次数由基线 5.6±0.3 次降至 1.3±0.2 次,ICIQ-OABqol 改善 34 分。
- 无器械相关严重不良事件。
核心结论
- Axonics r-SNM 系统安全有效,90% 参与者的尿急迫性尿失禁症状获得有临床意义且统计学显著的改善。
研究设计与样本
- ARTISAN-SNM 关键研究,共治疗 129 例符合条件的尿急迫性尿失禁患者,所有参与者均以非分期手术植入倒钩电极和可充电骶神经调控系统,采用 as-treated 分析。
- 疗效数据通过 3 天膀胱日记、经验证的 ICIQ-OABqol 问卷和参与者满意度问卷收集。
主要发现
- 6 个月时 90% 参与者为治疗应答者(尿急迫性尿失禁发作较基线减少≥50%)。
- 每日尿急迫性尿失禁发作次数均值±标准误由基线 5.6±0.3 次降至 1.3±0.2 次。
- 参与者在 ICIQ-OABqol 问卷上获得 34 分的临床有意义改善。
- 无器械相关严重不良事件。
关键数值与推荐
- 治疗应答定义为尿急迫性尿失禁发作较基线减少 50% 或以上。
- 6 个月时 90% 参与者达到治疗应答。
- 每日尿急迫性尿失禁发作均值±标准误:基线 5.6±0.3 次 vs 6 个月 1.3±0.2 次。
- ICIQ-OABqol 问卷改善 34 分。
临床怎么用
- 对于保守治疗失败的尿功能障碍和粪失禁患者,骶神经调控是指南推荐的治疗。
- Axonics r-SNM 系统设计可提供至少 15 年治疗,可能消除因电池耗竭而更换植入神经刺激器的手术需求。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Sacral neuromodulation is a guideline recommended treatment of urinary dysfunction and fecal incontinence in patients in whom conservative treatments have failed. Historically sacral neuromodulation has been delivered using a nonrechargeable device with an average life span of 4.4 years. Surgery is required to replace the implanted neurostimulator due to battery depletion. Implantation of a long-lived implanted neurostimulator can eliminate the need for replacement surgeries, potentially reducing patient surgical risks and health care costs. The Axonics r-SNM System™ is a miniaturized, rechargeable sacral neuromodulation system designed to deliver therapy for at least 15 years. The ARTISAN-SNM (Axonics® Sacral Neuromodulation System for Urinary Urgency Incontinence Treatment) study is a pivotal study using rechargeable sacral neuromodulation therapy to treat urinary urgency incontinence. Six-month results are presented. MATERIALS AND METHODS: A total of 129 eligible patients with urinary urgency incontinence were treated. All participants were implanted with a tined lead and the rechargeable sacral neuromodulation system in a nonstaged procedure. Efficacy data were collected using a 3-day bladder diary, the validated ICIQ-OABqol (International Consultation on Incontinence Questionnaire Overactive Bladder quality of life) questionnaire and a participant satisfaction questionnaire. Therapy responders were identified as participants with a 50% or greater reduction in urinary urgency incontinence episodes compared to baseline. We performed an as-treated analysis in all implanted participants. RESULTS: At 6 months 90% of participants were therapy responders. The mean ± SE number of urinary urgency incontinence episodes per day was reduced from 5.6 ± 0.3 at baseline to 1.3 ± 0.2. Participants experienced a clinically meaningful 34-point improvement on the ICIQ-OABqol questionnaire. There were no serious device related adverse events. CONCLUSIONS: The Axonics r-SNM System is safe and effective with 90% of participants experiencing clinically and statistically significant improvements in urinary urgency incontinence symptoms.
引用
- McCrery R, Lane F, Benson K, et al. Treatment of Urinary Urgency Incontinence Using a Rechargeable SNM System: 6-Month Results of the ARTISAN-SNM Study. J Urol. 2019. PMID: 31347955. doi:10.1097/JU.0000000000000458
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。